Drugs / ILKN421H
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07452224 | Jun 2026 → Jun 2029 expected | non-small cell lung carcinoma | iLeukon Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ILKN421H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07452224 ↗ |
| Route | Intravenous | “ILKN421H will be administered via i.v. infusion” NCT07452224 ↗ |